Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies
Journal of Translational Medicinevolume 9, Article number: 172 (2011)
Oncolytic viral tumor therapy is an emerging field in the fight against cancer with rising numbers of clinical trials and the first clinically approved product (Adenovirus for the treatment of Head and Neck Cancer in China) in this field. Yet, until recently no general (bio)marker or reporter gene was described that could be used to evaluate successful tumor colonization and/or transgene expression in other biological therapies.
Here, a bacterial glucuronidase (GusA) encoded by biological therapeutics (e.g. oncolytic viruses) was used as reporter system.
Using fluorogenic probes that were specifically activated by glucuronidase we could show 1) preferential activation in tumors, 2) renal excretion of the activated fluorescent compounds and 3) reproducible detection of GusA in the serum of oncolytic vaccinia virus treated, tumor bearing mice in several tumor models. Time course studies revealed that reliable differentiation between tumor bearing and healthy mice can be done as early as 9 days post injection of the virus. Regarding the sensitivity of the newly developed assay system, we could show that a single infected tumor cell could be reliably detected in this assay.
GusA therefore has the potential to be used as a general marker in the preclinical and clinical evaluation of (novel) biological therapies as well as being useful for the detection of rare cells such as circulating tumor cells.
The regained interest in oncolytic viruses over the past several years led to an enormous leap in the field with more and more oncolytic viruses to be described and yet to come. Not only were those viruses genetically altered to attenuate their virulence, to improve their safety profile and enhance their tumor specificity, but they also were equipped with additional genes for e.g. cytotoxins, cytokines, prodrug converting enzymes and reporter genes that improved the overall performance of these viruses [1, 2]. Among those, vaccinia virus is one of the most promising candidates and has several advantages: Since this large DNA virus encodes e.g. its own DNA polymerase it is able to replicate in the cytoplasm of infected host cells thereby minimizing the risk of DNA integration into the host genome. Moreover, vaccinia virus displays a broad host cell range, rapid spread and a high capacity (up to 25 kbp) for genetic payload of foreign DNA . Of note and importance regarding the safety of vaccinia virus, is also its billion-fold use in humans during the eradication program of smallpox, as well as the fact that vaccinia virus is not a human pathogen. On top of that, recombinant vaccinia virus strains (rVACVs) specifically colonize solid tumors in mice while not infecting other organs [4–7]. Therefore, its use in human patients was pursued and first human trials have already been carried out successfully [8–11].
A reliable monitoring of successful tumor colonization in humans would have an enormous impact not only on clinical trials, but also to predict possible outcomes of oncolytic virus therapy. In this aspect, we and others used different kind of reporter genes for optical (e.g. ), or radiological (e.g. [12–15]) imaging modalities. This enabled visualization of virus replication within live animal models. However, as optical imaging has strong limitations in penetration depth and radiological imaging is time consuming and requires the need of specialized personnel and expensive equipment, a cheap and simple method with short turn-around-times is urgently needed. In particular, if this method could also be used in other biological therapy approaches.
Beta-glucuronidases catalyze the hydrolysis of ß-D-glucuronides into the corresponding D-glucuronate and alcohol. While the mammalian enzymes with a pH-optimum under acidic conditions (pH 4 to 5) have strongly reduced capacity at normal (neutral) tissue pH, the E. coli enzyme encoded by gusA works optimal in the range of pH 6.8 to 7.7 .
Its first use as a (fusion-)reporter gene was described by Jefferson et al. [17, 18] and was extensively used in plant physiology studies. In mammals, bacterial glucuronidase was mainly used in prodrug studies, due to the very low abundance of human glucuronidase in human serum . Several strategies were successfully employed: e.g. fusion of cancer specific antibody-fragments with beta-glucuronidase  or tumor selective expression of the enzyme using bacteria  or adenoviruses [22, 23]. The reporter gene properties of the enzyme were not studied as extensively in animals. However, two independent approaches were published that looked at the potential of using beta-glucuronidase as a target structure for radiotracers in positron-emission-tomography [24, 25]. In another study, a membrane-anchored form of a mouse-glucuronidase was used in combination with the fluorescein di-beta-D-glucuronide (FDGlcU) which was hydrolyzed to a fluorescent reporter that could be used to assess the location and persistence of gene expression in vivo .
Here, we show that beta-glucuronidase in combination with fluorogenic substrates cannot only be used for localization of enzyme expression, but also as a general biomarker for foreign protein expression in serum samples. Consequently, the described test-system could be applied to all kinds of biological therapies which depend on heterologous gene expression.
Materials and methods
For evaluation of the described glucuronidase assay it was necessary to confirm the heterologous gene expression of the described vaccinia virus strain by Western blot analysis as well as immuno-staining studies in cell culture and infected tumor sections. The assay itself (described in the "Fluorogenic probes and detection of fluorescence products" section) was tested with purified enzyme as well as with samples from vaccinia virus injected animals.
Human A549 lung cancer cells (ATCC No. CCL-185) were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (PAA Laboratories, Cölbe, Germany) under standard cell culture conditions (37°C, 5% CO2). MTH52c is derived from a malignant small-cell canine carcinoma of the mammary gland  and cultured in DMEM supplemented with antibiotic-antimycotic solution and 20% FBS.
The attenuated vaccinia virus strain GLV-1h68 was purified as previously described . For generation of control viruses, lacZ and gusA of GLV-1h68 were replaced by nonrelevant gene constructs to create viruses negative for beta-galactosidase (rVACV-LacZ-) and beta-glucuronidase (rVACV-GusA-) respectively (Additional File 1, Figure S1).
Infection of cell cultures
Two days before infection, cells were seeded in 6-well plates for western blot analysis or 12-well plates containing sterile cover slips for microscopy studies. 90% confluent cell layers were either mock treated or infected with GLV-1h68, rVACV-LacZ- or rVACV-GusA- at a multiplicity of infection (MOI) of 0.1 for 1 h at 37°C and 5% CO2 in medium containing 2% FBS. Afterwards the infection medium was aspirated and replaced by standard cell culture medium.
Western blot analysis
For detection of proteins, infected cells were harvested and lysed in SDS sample buffer at 6, 12, 24 and 48 hours post-infection (hpi). Lysates were separated by 10% SDS-Polyacrylamide gel electrophoresis and subsequently transferred onto a nitrocellulose membrane (Whatman GmbH, Dassel, Germany). After blocking in 5% skim milk in PBS, the membrane was incubated with anti-beta-glucuronidase rabbit polyclonal antibody (G5420, Sigma-Aldrich, Schnelldorf, Germany), anti-beta-galactosidase rabbit polyclonal antibody (A-11132, Molecular Probes, Leiden, Netherlands), anti-GFP rabbit polyclonal antibody (sc-8334, Santa Cruz, Heidelberg, Germany) or anti-beta-actin mouse monoclonal antibody (ab6276, Abcam, Cambridge, UK). The first antibodies were detected using horseradish peroxidase-conjugated anti-mouse (ab6728, Abcam, Cambridge, UK) or anti-rabbit (ab6721, Abcam, Cambridge, UK) secondary antibodies, followed by enhanced chemiluminescence detection.
X-Gal/X-GlcU staining and microscopy studies
For the analysis of expression and activity of beta-galactosidase and beta-glucuronidase respectively, A549 cells were seeded on coverslips and infected with 200 PFU GLV-1h68, rVACV-LacZ- or rVACV-GusA- per well. After incubation for 2 days, cells were fixed using 4% paraformaldehyde and washed twice in PBS. Staining solutions consisted of 40 μl X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside, Invitrogen, Karlsruhe, Germany) and X-GlcU (5-bromo-4-chloro-3-indolyl-β-D-glucuronide, Invitrogen, Karlsruhe, Germany) respectively in dimethylformamide (40 mg ml-1), ferricyanide (12 mM K3Fe(CN)6), 5.2 mM MgCl2 and ferrocyanide solution (12 mM K4Fe(CN)6). Coverslips were stained with either X-Gal or X-GlcU solution and incubated for 24 h at 37°C before mounting in Mowiol. Images were taken with a Zeiss Axiovert 200 M microscope.
Histology and immunofluorescence
For histological analysis, snap-frozen tumors were fixed in 4% paraformaldehyde/PBS overnight at 4°C. Samples were embedded in 5% (w/v) low-melt agarose (AppliChem, Darmstadt, Germany) und 100 μm sections were cut using a Leica VT1000S Vibratome (Leica, Heerbrugg, Switzerland) as described before . After permeabilizing in 0.3% Triton X-100/PBS, sections were incubated with Hoechst 33342, anti-beta-glucuronidase rabbit polyclonal antibody (G5420, Sigma-Aldrich, Schnelldorf, Germany) and anti-beta-galactosidase chicken polyclonal antibody (ab9361, Abcam, Cambridge, UK) before staining with Cy-5-conjugated donky anti-rabbit and Cy-3 conjugated donky anti-chicken secondary antibodies (Jackson ImmunoResearch, West Grove, PA). Mowiol-embedded sections were examined using a Leica MZ 16 FA Stereo-Fluorescence Microscope equipped with a Leica DC500 Digital Camera. Digital Images were processed with Photoshop 7.0 (Adobe Systems, San Jose, CA) and merged to yield pseudocolored pictures.
A549 and MTH52c xenograft tumors were developed in 6- to 8-week-old nude mice (NCI:Hsd:Athymic Nude Foxn1nu, Harlan Borchem, Germany) by implanting 5 × 106 cells subcutaneously in the right abdominal flank. Two to three weeks after implantation, mice were anesthetized with isoflurane and injected with a viral dose of 5 × 106 PFU GLV-1h68, rVACV-LacZ- or rVACV-GusA- in 100 μl PBS via the retro-orbital sinus vein.
Blood and urine collection of mice was carried out under anesthesia by a heparinised capillary pipet (No. 554/20, Assistent, Sondheim, Germany) via the retro-orbital sinus vein for blood and a bladder catheter (No. 381312, Becton Dickinson, Heidelberg, Germany) for urine respectively.
All animal experiments were carried out in accordance with protocols approved by the Regierung von Unterfranken (Würzburg, Germany) (protocol number AZ 55.2-2531.01-17/08) and/or the the Institutional Animal Care and Use Committee (IACUC) of Explora BIOLABS, located in San Diego Science Center (San Diego, USA) (protocol number: EB08-003).
Fluorogenic probes and detection of fluorescence products
The lyophilized fluorogenic probes FDGlcU, FDG and 4-Methylumbelliferyl-b-D-glucuronide (4-MUG) (Invitrogen, Karlsruhe, Germany) were dissolved in DMSO (36.5 mM). For in-vivo studies, 5 μl of each stock dilution was mixed with 195 μl PBS and injected intraperitoneally. Whole body and urine fluorescence analysis was performed using a Maestro EX imaging system (CRI, Woburn, MA). For serum analysis, the collected mouse serum was diluted 1:15 with PBS and 80 μl of each sample were mixed with of either 2.5 μg FDGlcU or 1.5 μg 4-MUG if not otherwise indicated. Human serum of healthy individuals (Zen-Bio Inc, Research Triangle, NC) was obtained from whole blood and 10 μl were used in the described assay. After incubation for 1 h at 37°C (if not otherwise indicated), fluorescence was read in Lumox 384-well plates (Sarstedt, Nümbrecht, Germany) using an Infinite 200 Pro Microplate Reader (Tecan, Crailsheim, Germany) or a Spectra Max M5 (Molecular Devices, Sunnyvale, USA) and fluorescence intensities are listed as relative fluorescence units.
Biological therapies, like e.g. oncolytic virotherapy, are dependend on the expression of genes that are not functionally expressed in the respective patient. We recently described the use the rVACV strain GLV-1h68 in combination with a prodrug seco-analog of duocarmycin SA which is activated by the virus encoded beta-galactosidase . Although very promising results were observed in cell culture, the synergistic effect in tumor bearing mice were less pronounced, which was also true for a bacterial glucuronidase activatable version of the prodrug (Hess et al, unpublished). Among other potential reasons for this observation was a non-favorable pharmacokinetic of the prodrugs. Therefore, we wanted to analyze the activation and pharmacokinetics of other beta-galactosidase or glucuronidase substrates that could actually be visualized by optical imaging.
As fluorescent probes can be directly detected in small animals, the compounds FDG (substrate for the beta-galactosidase LacZ) as well as FDGlcU (a glucuronidase substrate) were injected in tumor bearing mice that had previously been injected with oncolytic rVACV (GLV-1h68) encoding both enzymes. Upon cleavage the probes were converted to fluorescein which resulted in a change of their fluorescent properties that was readily detectable with a small animal fluorescence imaging system (Figure 1A). Animals that were previously injected with PBS or the control rVACV strains not expressing beta-galatosicase (rVACV-LacZ-) and glucuronidase (rVACV-GusA-) respectively served as controls. It became evident that each fluorogenic probe could indeed be activated in the tumor and that this activation is dependent on the expression of LacZ and GusA respectively (Figure 1A and 1C). The maximum fluorescein fluorescence in the tumor was observed 120 min after intraperitoneal injection (Figure 1B). Upon intravenous FDGlcU-injection the maximum fluorescence was already observed 20 min post injection (Additional File 2, Fig. S2). About 6 hours post injection (hpi), the GFP-dependent fluorescence remained while most of the compound specific fluorescence was gone (Figure 1A and 1B).
Consequently it was investigated how the produced fluorescein was removed from the tumor. Possible explanations could be fluorescein instability in or compound excretion from the tumor.
In favour of (renal) excretion was the presence of fluorescein in the urine of injected mice. Moreover, when fluorescein itself was injected directly into the tumor the compound accumulated in the bladder and was then secreted with the urine (data not shown) while it disappeared from the tumor.
The presence of the activated probe in the urine of GLV-1h68 injected tumor bearing mice offered the possibility to evaluate this as a possible biomarker for successful tumor colonization. To test this, mice were anesthesized and urine was isolated via a bladder cathether before and 90 minutes after i.p. injection of FDGlcU. Indeed, fluorescein was present in urine of GLV-1h68 treated tumor bearing animals but could not be observed in FDGlcU injected control mice that either had non-colonized or rVACV-GusA- colonized tumors (Figure 2A, B). Therefore, one could establish a test for the presence of GLV-1h68 in tumors of live mice with a simple urine test after systemic injection of FDGlcU. Nevertheless, we did not proceed to establish a urine based test system as the injection of FDGlcU in human patients seemed unlikely.
Although fluorescein obviously was renally excreted, it was also investigated whether active enzymes that were specifically produced in the tumor tissue leaked out and were then present in the serum of GLV-1h68 injected tumor bearing mice leading to additional (non-tumor specific) cleavage of FDGlcU. To investigate this, the serum of tumor bearing mice which were previously injected with the GusA encoding strain GLV-1h68 was incubated with FDGlcU or 4-MUG. Both substances can be hydrolysed by glucuronidase to the fluorescent products fluorescein and 4-MU respectively. As latter has excitation and emission maxima of 365 nm and 455 nm respectively, it was not suitable for optical in vivo imaging and therefore only used in in vitro studies. In our experiments, no fluorescence was observed when mice were injected with PBS or GusA-negative control rVACV while the fluorescent compounds clearly were detectable after co-incubation with serum derived from GLV-1h68 injected mice (Figure 3A). The serum therefore contained active (non-secreted, but shed) enzymes that were produced in the tumor tissue.
Theoretically, this does pave the way to a simple blood test that could be used to distinguish tumor bearing from healthy patients and/or to distinguish between successful from unsuccessful tumor colonization of GusA-encoding oncolytic virus strains in cancer bearing patients. To confirm this, we retrospectively tested serum samples (n = 99) from different tumor xenograft models (GI-101A, A549, DU-145, PANC-1, HT-29) that were collected in our lab over about 4 years from mice injected with PBS (n = 33) or treated for different periods of time (7 to 53 days) with several GusA-positive (n = 53) or -negative (n = 13) rVACV (Figure 3B). The test of these probes confirmed a significant (p < 0.001) difference between the GusA containing group and those that did not result in GusA-production. As the test was done in retrospect, we could not confirm/exclude successful tumor colonization in those mice which had GusA-negative results in the blood test. This could explain the negative results for 5 of the GusA-rVACV injected tumor bearing mice.
Next, it was investigated whether one could confidently decide via the blood test if a tumor was colonized or not. Tumor bearing mice (n = 5) were systemically injected with a low dose (1 × 105 PFU) of GLV-1h68. This dose was known to result in colonization of only some tumors while other tumors do not get colonized at all. Serum was then isolated 1, 3, 7, 10 and 14 days later, before mice were sacrificed and tumor colonization was tested by conventional plaque assay confirming the results observed by the FDGlcU/4-MUG based blood test (Figure 4A). The very same 2 out of 5 mice were found to have GLV-1h68 in their tumors as well as being positive in the FDGlcU/4-MUG based blood tests.
In another experiment we tested the suitability of the blood test to differentiate between tumor bearing and control tumor free mice. Unexpectedly, seven days post injection of GLV-1h68 in non-tumor bearing mice low but significant glucuronidase activity was detected in the serum of tumor free mice. Closer examination of those mice revealed GFP expression in the paws of 2 mice (data not shown). Therefore, the mice were sacrificed and a plaque assay of several organs was used to find the origin of glucuronidase production (Table 1). Apart from the two infected paws virus was reproducibly isolated in low concentration from ovaries of non-tumor bearing mice. Interestingly, ovaries of tumor bearing mice were essentially free of virus.
Background expression of glucuronidase in healthy subjects would of course exclude using this test system for detection of tumors if no difference existed that allowed differentiation between cancer patients and healthy individuals. Time course studies in male (n = 12 tumor bearing and 12 tumor free) and female mice (n = 24 tumor bearing and 6 tumor free) over a period of 14-16 days in which blood was taken every other day (in one half of the mice blood was taken on even, in the other on uneven days post virus injection), again showed low levels of glucuronidase present in the serum of tumor free mice. These were similar to those observed in tumor bearing mice until 8 days post virus injection (Figure 4B and Additional File 3, Fig. S3). After that however, significant changes occurred. While the glucuronidase activity in the serum of tumor free mice decreased, the fluorescence signal in the tumor bearing animal probes increased.
Taken together, 9 days after injection of the virus it was possible to decide with confidence whether A) an existing tumor was successfully colonized and/or B) a tumor was present in the gusA encoding rVACV injected mouse.
In a next step the sensitivity and performance of the described test was evaluated in in vitro studies regarding its clinical translatability. We found a positive correlation between the fluorescence signal intensities and increasing A) glucuronidase concentration, B) substrate (FDGlcU or 4-MUG) concentration and C) incubation time (Additional File 4, Fig. S4). The data also revealed that very low glucuronidase concentrations could be detected using the fluorogenic FDGlcU or 4-MUG substrates which should allow detection of lysed tumor cells not only in mice but also in humans. Feasibility in the presence of human serum was shown by running the assay in the presence or absence of 10 μl human serum (Additional File 5, Fig. S5). The data revealed that neither the sensitivity nor the fluorescence intensity of the assay was changed in the presence of human serum.
As the presence of glucuronidase relies on the production by infected cancer cells, the minimal amount of infected cancer cells was tested that was needed to generate a positive fluorescent signal. For this, A549 cells were infected with GLV-1h68 or control-rVACV. One day later, the amount of infected cells was determined by counting and flow cytometry and the cells were diluted and seeded in half-log dilutions in 384-well plates with concentrations varying from approx. 1.0 to 1000 infected cells/well and co-incubated with 6.3 μg FDGlcU and 3.4 μg 4-MUG respectively. To obtain high sensitivity, the probes were incubated at 37°C over night and analyzed the next day (Figure 5). Surprisingly, even a single infected cancer cell could be readily detected using this test when using 4-MUG as a substrate. This allowed us to calculate the potential sensitivity of the described test for the detection of tumors in human patients using two different approaches: 1) Assuming that more serum (e.g. 50 μl) would be used when testing the system on human patient samples, and an average total blood volume of about 4.7 liters, only approx. 105 infected cancer cells would be sufficient to generate a detectable fluorescent signal. 2) The fluorescent signal generated from a single cancer cell was similar to that obtained from 0.2 units glucuronidase. Increasing the sensitivity by adding more fluorescent substrate 0.05 units glucuronidase were easily detectable, corresponding to a concentration of 1 unit glucuronidase/ml serum (again using 50 μl serum/test) or 4700 units/average blood volume of a human patient. Therefore, as low as 2.4 × 104 infected cancer cells would be sufficient for a positive signal.
Biological therapies including stem cell therapy, gene therapy, immunotherapy, oncolytic virotherapy etc. are gaining more and more impact in e.g. regenerative medicine, immunology, oncology and treating various diseases. All of these require the expression of certain genes that usually are not or only weakly expressed in the targeted tissue. While progress in terms of biological effectiveness is made in each field, no common reporter system exists which is cost-efficient, easy to use in clinical laboratories and at the same time allows short turn-around-times.
In our studies we used oncolytic rVACV strains as a model to investigate the potential of a (bacterial) beta-glucuronidase in combination with fluorogenic probes to be used as a general reporter system in biological therapies. The bacterial glucuronidase was chosen as reporter gene, since the pH in blood (pH of about 7.4) is in the pH-optimum range (pH 6.8 - 7.7) of the bacterial enzyme  while mammalian beta-glucuronidases are most active at pH 4 to 5 and present almost exclusively in lysosomes. Moreover, the bacterial enzyme displays much higher specific activity compared to the human beta-glucuronidase . On the other hand, bacterial enzymes usually have much higher immunogenicity than their mammalian counterparts and thus might be hindered in their efficacy . Consequently, the group of S. Roffler selected mutants of human beta-glucuronidase with enhanced activity at neutral pH  and fused this protein to single chain humanized antibodies for enhanced antibody-directed enzyme prodrug therapy . Therefore, it should also be possible to use this optimized human beta-glucuronidase in the detection system described herein.
Furthermore, the possibility to direct active beta-glucuronidase into the cytoplasm (this study and many others, e.g. ), attach it to the cell surface (e.g. [23, 33]), or secrete from producing cells (e.g. [32, 34]) offers a number of different potential applications.
Cytoplasm associated beta-glucuronidase seems to be a very attractive marker for oncolytic viruses. Not only does presence of glucuronidase in the serum show successful tumor colonization, but also indicates a therapeutic effect: Active enzyme can only get in the serum when (tumor) cells are lysed. Future studies will show if responding and non-responding tumors can be differentiated using the described test system.
The detection of cell surface associated beta-glucuronidase could be helpful in studies relying on transfection of cells or following bacteria or parasite infections in which blood-borne pathogens express a membrane- or cell-wall-anchored glucuronidase. Also, the previously mentioned (non-membrane passing) prodrug therapies would benefit from detection of beta-glucuronidase in the blood: The enzyme would only be observed upon successful prodrug treatment as only then, the active enzyme is released from the tumor.
Secreted beta-glucuronidase could be used as a simple marker for cell survival. Genetically altered cells should secrete active enzyme as long as they are viable. Again, a small number of cells would be sufficient for detection and the amount of beta-glucuronidase in the blood should be correlating with the amount of cells producing the enzyme. Therefore, it will be possible to monitor e.g. stem cell therapies, tissue regeneration etc.
In each case one will have to decide whether the achieved enzyme concentration is sufficient to be detected in the respective assays. Here, we calculated that theoretically only 2.4 × 104 vaccinia virus infected cancer cells might be enough to be detected in humans. With a diameter of 50 μm/cell this would correspond to a volume of only 1.6 mm3. Of course, it can be argued that in patients this number might be higher, as e.g. not all virus infected cells will release all of their enzymes into the blood stream upon lysis. But even if the number of infected cells is 10 or even 100-fold higher, the tumor diameter would only be 3.1 and 6.7 mm, respectively. Nevertheless, only clinical trials such as those in which GLV-1h68 is currently evaluated for safety in human cancer patients , will determine whether the proposed detection system can be translated to a clinical setting.
Presumably, similar evaluations will be necessary when applying the presented beta-glucuronidase test in other applications such as in infectious disease studies, stem cell research/therapy etc. both in basic as well as in translational research.
Taken together, we demonstrated that glucuronidase (in our case encoded by rVACV) in combination with fluorogenic probes has the potential to be used as a general reporter system for heterologous gene expression in biological therapies. Our results provide evidence that the described system cannot only be used for imaging of tumors in the body, but also to confirm viral colonization of these tumors or even the diagnosis of tumors in screening studies.
fetal bovine serum
Green fluorescent protein
multiplicity of infection
plaque forming units
recombinant vaccinia virus strain
Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009, 9: 64-71. 10.1038/nrc2545.
Garcia-Aragoncillo E, Hernandez-Alcoceba R: Design of virotherapy for effective tumor treatment. Curr Opin Mol Ther. 2010, 12: 403-411.
Moss B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 1996, 93: 11341-11348. 10.1073/pnas.93.21.11341.
Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA: Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67: 10038-10046. 10.1158/0008-5472.CAN-07-0146.
Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA: Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004, 22: 313-320. 10.1038/nbt937.
Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL: Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 2000, 7: 66-73. 10.1038/sj.cgt.7700075.
Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA: Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther. 2009, 16: 320-328. 10.1038/cgt.2008.87.
Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K: Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy. Mol Ther. 2011, 19: 1170-1179. 10.1038/mt.2011.39.
Liu TC, Hwang T, Park BH, Bell J, Kirn DH: The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008, 16: 1637-1642. 10.1038/mt.2008.143.
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9: 533-542. 10.1016/S1470-2045(08)70107-4.
Pedersen J, Karapanagiotou L, Alam S, Puglisi M, Britton L, Sassi S, Mansfield D, Yap T, De-Bono J, Harrington K: Preliminary results of a Phase 1 study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging. 2010, 6th NCRI Cancer Conference; BT Convention Center, Liverpool, UK
Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, Hackman T, Balatoni J, Finn R, Larson SM: Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med. 2001, 7: 859-863. 10.1038/89991.
Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA: A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med. 2009, 15: 144-151.
Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004, 103: 1641-1646. 10.1182/blood-2003-07-2233.
Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A: Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med. 2011, 9: 36-10.1186/1479-5876-9-36.
Fang W, Vikerpuur M, Sandholm M: A fluorometric beta-glucuronidase assay for analysis of bacterial growth in milk. Vet Microbiol. 1995, 46: 361-367. 10.1016/0378-1135(95)00044-B.
Jefferson RA, Burgess SM, Hirsh D: beta-Glucuronidase from Escherichia coli as a gene-fusion marker. Proc Natl Acad Sci USA. 1986, 83: 8447-8451. 10.1073/pnas.83.22.8447.
Jefferson RA, Kavanagh TA, Bevan MW: GUS fusions: beta-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO J. 1987, 6: 3901-3907.
Stahl P, Fishman W: Beta-D-glucuronidase. Methods in enzymatic analysis. Edited by: JB, MG. 1984, Weinheim, Germany: Verlag Chemie, 246-256.
Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR: Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 1992, 52: 4484-4491.
Cheng CM, Lu YL, Chuang KH, Hung WC, Shiea J, Su YC, Kao CH, Chen BM, Roffler S, Cheng TL: Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther. 2008, 15: 393-401. 10.1038/cgt.2008.10.
de Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ, Boven E: Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Hum Gene Ther. 2004, 15: 229-238. 10.1089/104303404322886084.
Huang PT, Chen KC, Prijovich ZM, Cheng TL, Leu YL, Roffler SR: Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. Cancer Gene Ther. 2011, 18: 381-389. 10.1038/cgt.2011.3.
Tzou SC, Roffler S, Chuang KH, Yeh HP, Kao CH, Su YC, Cheng CM, Tseng WL, Shiea J, Harm IH: Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. Radiology. 2009, 252: 754-762. 10.1148/radiol.2523082055.
Antunes IF, Haisma HJ, Elsinga PH, Dierckx RA, de Vries EF: Synthesis and evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity. Bioconjug Chem. 2010, 21: 911-920. 10.1021/bc9004602.
Su YC, Chuang KH, Wang YM, Cheng CM, Lin SR, Wang JY, Hwang JJ, Chen BM, Chen KC, Roffler S, Cheng TL: Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. Gene Ther. 2007, 14: 565-574. 10.1038/sj.gt.3302896.
Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, Eberle N, Nolte I, Bullerdiek J, Murua Escobar H: Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene. 2009, 434: 35-42. 10.1016/j.gene.2008.10.027.
Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA: Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007, 297: 151-162. 10.1016/j.ijmm.2007.01.008.
Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, von Hof JM, Krewer B, Tietze LF, Gentschev I, Szalay AA: Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Ther. 2011, 18: 42-52. 10.1038/cgt.2010.49.
Chen KC, Wu CH, Chang CY, Lu WC, Tseng Q, Prijovich ZM, Schechinger W, Liaw YC, Leu YL, Roffler SR: Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. Chem Biol. 2008, 15: 1277-1286. 10.1016/j.chembiol.2008.10.008.
Sharma SK, Bagshawe KD, Melton RG, Sherwood RF: Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. 1992, 21: 109-120.
Chen KC, Wu SY, Leu YL, Prijovich ZM, Chen BM, Wang HE, Cheng TL, Roffler SR: A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. Bioconjug Chem. 2011, 22: 938-948. 10.1021/bc1005784.
Heine D, Muller R, Brusselbach S: Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther. 2001, 8: 1005-1010. 10.1038/sj.gt.3301474.
Weyel D, Sedlacek HH, Muller R, Brusselbach S: Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 2000, 7: 224-231. 10.1038/sj.gt.3301072.
We like to thank Q. Zhang, N. Chen, T. Trevino and J. Aguilar for providing all rVACV, A. Seidensal and J. Langbein for excellent technical assistance. This work was supported by Genelux Corporation (R&D facility in San Diego, CA, USA) and Genelux GmbH, a Service Grant to the University of Würzburg, Germany also funded by Genelux Corp., San Diego, USA as well as a grant of the "Bundesministerium für Bildung und Forschung" in the MoBiTech initiative (grant number 13N4051). JS, BH, IG and AAS are employees and shareholders of Genelux Corporation and Genelux GmbH respectively. MH and JBS are supported by graduate stipends from Genelux Corporation, San Diego.
The research was supported by the Research and Development Division of Genelux Corp., San Diego, USA, and a Service Grant to the University of Würzburg, Germany also funded by Genelux Corp., San Diego, USA as well as a grant of the "Bundesministerium für Bildung und Forschung" in the MoBiTech initiative (grant number 13N4051). JS, BH, IG and AAS are employees and shareholders of Genelux Corporation and Genelux GmbH respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No competing interests exist for MH and JBS.
MH and JS conceived the study, designed, performed and analyzed all experiments and wrote the manuscript. JBS and BH participated in live animal studies. IG participated in manuscript writing. AAS participated in conceiving the study and writing the manuscript. All authors read and approved the final version of the manuscript.
Michael Hess, Jochen Stritzker contributed equally to this work.